A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorShanghai AbelZeta Ltd.
About this trial
This is a multicenter, single arm, open-label study. The purpose of the study is to evaluate safety of Prizloncabtagene Autoleucel (Prizlon-cel) and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of Prizlon-cel (Phase 2) in patients with relapsed or refractory large b-cell lymphoma (LBCL).
Eligibility criteria
Qualifiers
≥ 18 years of age
Diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)
Primary mediastinal large B-cell lymphoma (PMBCL)
Transformed follicular lymphoma (tFL)
Disqualifiers
Prior allogeneic hematopoietic stem cell transplantation (HSCT) at anytime, or ASCT within 12 weeks prior to apheresis
Suspected or confirmed central nervous system involvement
Stroke or convulsion history within 6 months of signing informed consent form (ICF)
Autoimmune disease, immunodeficiency or diseases requiring immunosuppressants treatment
Trial design
Treatments tested in this trial
- Prizloncabtagene autoleucel
Treatment groups
112 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov